Department of Ophthalmology, University Hospital Basel, Mittlere Strasse 91, 4031 Basel, Switzerland.
EPMA J. 2010 Mar;1(1):73-7. doi: 10.1007/s13167-010-0003-8. Epub 2010 Apr 1.
Retinal vasculature changes in diabetic patients are most common cause of blindness among eye diseases. Numerous studies have explored the role of the agiogenic factors in the progression of diabetic retinopathy (DR). The balance between angiogenic and antiangiogenic factors has a determining role in the DR progression. Current treatment modalities include laser photocoagulation, intravitreal drug application, and pars plana vitrectomy (ppv). These maneuvers are employed with occurrence of advanced retinal changes. New diagnostic approaches can provide better information for the initial retinal changes thereby requiring a new DR classification and treatment guidelines. The results that are expected from Diabetic Retinopathy Clinical Research Network (DRCR) are at the level where prediction and prevention can not be made. Innovative molecular-imaging technology, can pave the way for application of novel clinical approaches. Identification of pathology-specific biomarkers and their application to diagnosis and treatment, support the individualized treatment algorithms.
糖尿病患者的视网膜血管变化是眼病致盲的最常见原因。大量研究探讨了血管生成因子在糖尿病视网膜病变（DR）进展中的作用。血管生成和抗血管生成因子之间的平衡在 DR 进展中起着决定性作用。目前的治疗方法包括激光光凝、眼内药物应用和玻璃体切除术（ppv）。这些操作适用于出现晚期视网膜改变的情况。新的诊断方法可以为初始视网膜改变提供更好的信息，从而需要新的 DR 分类和治疗指南。糖尿病视网膜病变临床研究网络 (DRCR) 的预期结果处于无法进行预测和预防的水平。创新的分子成像技术，可以为新的临床方法的应用铺平道路。病理学特异性生物标志物的鉴定及其在诊断和治疗中的应用支持个体化治疗算法。
